Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Dana D Hu-Lowe, Helen Y Zou, Maren L Grazzini, et al.Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.Journal of Medicinal Chemistry|May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutationsTed W Johnson, Paul F Richardson, Simon Bailey, et al.Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.Pageof 2